Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jan;107(2):173-80.
doi: 10.1172/JCI8525.

A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin

D G Alleva  1 , P D Crowe, L Jin, W W Kwok, N Ling, M Gottschalk, P J Conlon, P A Gottlieb, A L Putnam, A Gaur
Affiliations

A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin

D G Alleva et al. J Clin Invest. 2001 Jan.

Abstract

The 9-23 amino acid region of the insulin B chain (B9-23) is a dominant epitope recognized by pathogenic T lymphocytes in nonobese diabetic mice, the animal model for type 1 diabetes. We describe herein similar (B9-23)-specific T-cell responses in peripheral lymphocytes obtained from patients with recent-onset type 1 diabetes and from prediabetic subjects at high risk for disease. Short-term T-cell lines generated from patient peripheral lymphocytes showed significant proliferative responses to (B9-23), whereas lymphocytes isolated from HLA and/or age-matched nondiabetic normal controls were unresponsive. Antibody-mediated blockade demonstrated that the response was HLA class II restricted. Use of the highly sensitive cytokine-detection ELISPOT assay revealed that these (B9-23)-specific cells were present in freshly isolated lymphocytes from only the type 1 diabetics and prediabetics and produced the proinflammatory cytokine IFN-gamma. This study is, to our knowledge, the first demonstration of a cellular response to the (B9-23) insulin epitope in human type 1 diabetes and suggests that the mouse and human diseases have strikingly similar autoantigenic targets, a feature that should facilitate development of antigen-based therapeutics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Type 1 diabetic patient response to insulin B(9–23) peptide. A total of 105 T lymphocytes from short-term cell lines of B(9–23)-treated PBMCs from type 1 diabetic patients (i.e., P1–P12) were seeded per well of a 96-well round-bottom plate with 7 × 104 irradiated autologous PBMCs in the presence or absence of different concentrations of insulin B(9–23) peptide. Cells were cultured for 5 days in which each well was pulsed with [3H]thymidine for the final 18–20 hours, and the amount of incorporated radioactivity was counted. Values in all panels are the mean cpm ± SEM of triplicate cultures from one experiment representative of at least two experiments for all patients.
Figure 2
Figure 2
Role of HLA-DQ8 in insulin B(9–23)-specific response in a type 1 diabetic patient. A total of 105 T lymphocytes from short-term cell lines of B(9–23)-treated PBMCs from type 1 diabetic patient P2, homozygous for HLA-DR4 (DRB1*0402/0405) and DQ8 (DQB1*0302), were treated in the presence or absence of 20 μg/ml anti-DQ or anti-DR blocking antibody. These antibodies were added to stimulator autologous PBMCs 30 minutes before responder T cells were added. Cells were cultured for 5 days during which each well was pulsed with [3H]thymidine for the final 18–20 hours and the amount of incorporated radioactivity was counted. Isotype control antibody had no significant effect on proliferation. Values are the mean cpm ± SEM of triplicate cultures from one experiment representative of three experiments.
Figure 3
Figure 3
Example of cytokine responses to insulin B(9–23) by type 1 diabetic patients and control subjects. 3 × 105 freshly isolated PBMCs from two type 1 diabetic patients (P5 and P9) and two age-matched control subjects (C12 and C13) were seeded per well of a 96-well anti–IFN-γ mAb–coated ELISPOT assay plate in the presence or absence of insulin B(9–23) and incubated at 37°C for 24 hours. Spots representing IFN-γ–producing cells (denoted by the number in parentheses) were developed using a biotinylated anti–IFN-γ secondary antibody and avidin-labeled peroxidase with AEC substrate and quantified using the Series-1 Immunospot Analyzer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331:1428–1436. - PubMed
    1. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD [erratum 1998, 8:531] Immunity. 1997;7:727–738. - PubMed
    1. Durinovic-Bello I. Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens. Autoimmunity. 1998;27:159–177. - PubMed
    1. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol. 1994;24:1853–1857. - PubMed
    1. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol. 1995;25:1056–1062. - PubMed